Literature DB >> 22065876

In vivo near-infrared fluorescence imaging of integrin α2β1 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe.

Chiun-Wei Huang1, Zibo Li, Peter S Conti.   

Abstract

UNLABELLED: The overexpression of integrin α(2)β(1) has been demonstrated to correlate with prostate tumor aggressiveness and metastatic potential. Recently, we reported that the DGEA peptide is a promising targeting ligand for near-infrared fluorescence and microPET imaging of integrin α(2)β(1) expression in prostate cancers. Here, we aimed to further improve the targeting efficacy of this peptide by incorporating a series of cell-penetrating peptides (CPPs) into the DGEA sequence.
METHODS: After the conjugation with appropriate fluorescent dyes, the CPP-DGEA peptides were evaluated in human prostate cell lines (PC-3, CWR-22, and LNCaP) that contain different integrin α(2)β(1) expression levels. In addition, to reduce excess kidney uptake, a carboxypeptidase-specific sequence Gly-Lys was incorporated into the probe design, allowing for cleavage by the kidney brush border enzymes of the CPP before uptake by proximal tubule cells.
RESULTS: Although the CPP motif greatly facilitated the translocation of CPP-DGEA without affecting binding specificity in vitro, fluorescent dye-labeled CPP-DGEA demonstrated extremely high kidney uptake in vivo. Kidney uptake was dramatically decreased after a carboxypeptidase-specific peptide linker (Gly-Lys) had been incorporated into the probe design. The optimized probe demonstrated a prominent accumulation of activity in PC-3 tumor (integrin α(2)β(1)-positive). Receptor specificity was confirmed with blocking experiments and evaluation in a CWR-22 control tumor model with low α(2)β(1) expression.
CONCLUSION: This study demonstrated that the introduction of a CPP sequence can facilitate the internalization of an integrin-targeted peptide probe in vitro. Moreover, a cleavable peptide linker successfully reduced kidney uptake while preserving good tumor uptake in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065876     DOI: 10.2967/jnumed.111.091256

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

Review 1.  Fluorescent molecular imaging: technical progress and current preclinical and clinical applications in urogynecologic diseases.

Authors:  V M Alexander; P L Choyke; H Kobayashi
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 2.  Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology.

Authors:  Lydia Atangcho; Tejas Navaratna; Greg M Thurber
Journal:  Trends Biochem Sci       Date:  2018-12-15       Impact factor: 13.807

3.  Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.

Authors:  Ganesan Vaidyanathan; Choong Mo Kang; Darryl McDougald; Il Minn; Mary Brummet; Martin G Pomper; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2018-05-05       Impact factor: 2.408

4.  Physalis Mottle Virus-like Nanoparticles for Targeted Cancer Imaging.

Authors:  He Hu; Hema Masarapu; Yuning Gu; Yifan Zhang; Xin Yu; Nicole F Steinmetz
Journal:  ACS Appl Mater Interfaces       Date:  2019-05-10       Impact factor: 9.229

5.  Fabrication of self-assembled peptide nanoparticles for in vitro assessment of cell apoptosis pathway and in vivo therapeutic efficacy.

Authors:  Syed Faheem Askari Rizvi; Shuai Mu; Chunyan Zhao; Haixia Zhang
Journal:  Mikrochim Acta       Date:  2022-01-08       Impact factor: 5.833

6.  Molecular machines open cell membranes.

Authors:  Víctor García-López; Fang Chen; Lizanne G Nilewski; Guillaume Duret; Amir Aliyan; Anatoly B Kolomeisky; Jacob T Robinson; Gufeng Wang; Robert Pal; James M Tour
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

7.  (64)Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression.

Authors:  Zhanhong Wu; Shuanglong Liu; Indu Nair; Keiko Omori; Stephen Scott; Ivan Todorov; John E Shively; Peter S Conti; Zibo Li; Fouad Kandeel
Journal:  Theranostics       Date:  2014-05-24       Impact factor: 11.556

8.  Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis.

Authors:  James R Marthick; Joanne L Dickinson
Journal:  Prostate Cancer       Date:  2012-07-31

Review 9.  Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers.

Authors:  Catherine Lozza; Isabelle Navarro-Teulon; André Pèlegrin; Jean-Pierre Pouget; Eric Vivès
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

10.  Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer.

Authors:  Amanee D Salaam; Patrick Hwang; Roberus McIntosh; Hadiyah N Green; Ho-Wook Jun; Derrick Dean
Journal:  Beilstein J Nanotechnol       Date:  2014-07-01       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.